Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
In March it launched its first plastic-free toothbrush packaging, which included Sensodyne Pronamel and parodontax brushes in the US. Asia Pacific rollout of this commenced in Australia
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
At present 18 per cent of the local pharmaceutical market is under government's price control
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The company has been sold to Shinshin Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
